These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 10968249)
1. Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy. Azuma H; Oshima M; Ito K; Okuno A; Kawabata I; Banba K; Murahashi H; Sekine T; Kato Y; Ikebuchi K; Ikeda H Eur J Pediatr; 2000 Aug; 159(8):633-4. PubMed ID: 10968249 [TBL] [Abstract][Full Text] [Related]
2. Effect of interleukin 2 on intractable herpes virus infection and chronic eczematoid dermatitis in a patient with Wiskott-Aldrich syndrome. Azuma H; Sakata H; Saijyou M; Okuno A Eur J Pediatr; 1993 Dec; 152(12):998-1000. PubMed ID: 8131820 [TBL] [Abstract][Full Text] [Related]
3. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Dupré L; Trifari S; Follenzi A; Marangoni F; Lain de Lera T; Bernad A; Martino S; Tsuchiya S; Bordignon C; Naldini L; Aiuti A; Roncarolo MG Mol Ther; 2004 Nov; 10(5):903-15. PubMed ID: 15509508 [TBL] [Abstract][Full Text] [Related]
4. Defective actin reorganization and polymerization of Wiskott-Aldrich T cells in response to CD3-mediated stimulation. Gallego MD; Santamaría M; Peña J; Molina IJ Blood; 1997 Oct; 90(8):3089-97. PubMed ID: 9376590 [TBL] [Abstract][Full Text] [Related]
5. Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. Zhang J; Shehabeldin A; da Cruz LA; Butler J; Somani AK; McGavin M; Kozieradzki I; dos Santos AO; Nagy A; Grinstein S; Penninger JM; Siminovitch KA J Exp Med; 1999 Nov; 190(9):1329-42. PubMed ID: 10544204 [TBL] [Abstract][Full Text] [Related]
6. T cells of patients with the Wiskott-Aldrich syndrome have a restricted defect in proliferative responses. Molina IJ; Sancho J; Terhorst C; Rosen FS; Remold-O'Donnell E J Immunol; 1993 Oct; 151(8):4383-90. PubMed ID: 8409409 [TBL] [Abstract][Full Text] [Related]
7. Functional correction of T cells derived from patients with the Wiskott-Aldrich syndrome (WAS) by transduction with an oncoretroviral vector encoding the WAS protein. Strom TS; Gabbard W; Kelly PF; Cunningham JM; Nienhuis AW Gene Ther; 2003 May; 10(9):803-9. PubMed ID: 12704420 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome. Jyonouchi S; Gwafila B; Gwalani LA; Ahmad M; Moertel C; Holbert C; Kim JY; Kobrinsky N; Roy-Ghanta S; Orange JS Clin Immunol; 2017 Jun; 179():47-53. PubMed ID: 28232030 [TBL] [Abstract][Full Text] [Related]
9. WASp in immune-system organization and function. Thrasher AJ Nat Rev Immunol; 2002 Sep; 2(9):635-46. PubMed ID: 12209132 [TBL] [Abstract][Full Text] [Related]
18. Update of the Wiskott-Aldrich syndrome. From a new case report. Martín Mateos MA; Muñoz-López F; Cruz M Allergol Immunopathol (Madr); 1988; 16(2):113-9. PubMed ID: 3394592 [TBL] [Abstract][Full Text] [Related]
19. Gene therapy for Wiskott-Aldrich syndrome: here to stay. Candotti F Lancet Haematol; 2019 May; 6(5):e230-e231. PubMed ID: 30981782 [No Abstract] [Full Text] [Related]
20. Bone marrow transplantation in the Wiskott-Aldrich syndrome. Complete hematological and immunological reconstitution. Ochs HD; Lum LG; Johnson FL; Schiffman G; Wedgwood RJ; Storb R Transplantation; 1982 Nov; 34(5):284-8. PubMed ID: 6760485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]